Glaukos (NYSE:GKOS) reported earnings of ($0.15) per share missing Walls Streets expectations.

Glaukos (NYSE:GKOS) reported Q2 2018 earnings this Afternoon, coming in at ($0.15) per share, missing Wall Street’s estimates of ($0.12) per Share. Revenue for the quarter came in at $43.16 million beating analyst estimates of $40.51 million

Recent Insider Trading for Glaukos (NYSE:GKOS)

  • On 6/19/2018 Chris M Calcaterra, COO, sold 7,759 with an average share price of $44.01 per share and the total transaction amounting to $341,473.59.
  • On 6/15/2018 Chris M Calcaterra, COO, sold 8,771 with an average share price of $44.01 per share and the total transaction amounting to $386,011.71.
  • On 3/6/2018 Orbimed Advisors Llc, Director, sold 836,500 with an average share price of $32.02 per share and the total transaction amounting to $26,784,730.00.
  • On 3/2/2018 Jonathan Silverstein, Director, sold 464,583 with an average share price of $32.29 per share and the total transaction amounting to $15,001,385.07.
  • On 11/22/2017 Joseph E Gilliam, CFO, bought 2,100 with an average share price of $23.84 per share and the total transaction amounting to $50,064.00.
  • On 9/7/2017 Thomas William Burns, CEO, sold 73,788 with an average share price of $41.36 per share and the total transaction amounting to $3,051,871.68.
    Story continues below



    About Company
    Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. Its product pipeline also consists of iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure; and iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma. Glaukos Corporation markets its products through direct sales force in the United States and internationally, as well as through distribution partners in Europe, the Asia Pacific, Latin America, and internationally. The company was founded in 1998 and is headquartered in San Clemente, California.

    Recent Analyst Rating for Glaukos (NYSE:GKOS)



      Recent Trading for Glaukos (NYSE:GKOS)
      Shares of Glaukos closed the previous trading session at with 840900 shares trading hands.

      An ad to help with our costs